Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Alimentary pharmacology & therapeutics Singal, A. K., Kuo, Y., Reddy, K. R., Bataller, R., Kwo, P. 2022


BACKGROUND: Hepatorenal syndrome (HRS) contributes to significant morbidity and mortality in hospitalised patients with cirrhosis.AIMS: To examine recent trends, magnitude and outcomes of HRS, in National Inpatient Sample (NIS) database.METHODS: Among the NIS database on cirrhosis hospitalisations (2016-2019) due to alcohol (ALD), chronic viral hepatitis (CVH), or NASH and complicated by acute kidney injury (AKI) were analyzed.RESULTS: Of 113,454 hospitalisations, 18,735 (16.5%) had HRS (mean age 56years, 36% females, 68% whites, 80% ALD, 7% NASH) with a stable trend overtime. Among 1:1 propensity-matched 36,090 hospitalisations, the odds of HRS were 12% higher in NASH versus CVH. Based on weighted national estimates, there were 27,180 (8.3 per 100,000 US population) HRS hospitalisations in 2019, with economic burden of $4.2 billion USD. Mean hospitalisation and total charges (ALD vs. CVH vs. NASH) were 11 versus 10.8 versus 9.2days and 151,000 versus 157,000 versus 120,000 USD, respectively; p<0.001. In-hospital mortality was 18.9%, higher in HRS (25.8 vs. 12%, p<0.001), and decreased by 15% annually. Survivors were more likely to be discharged to short- or long-term care facilities (HRS vs. non-HRS [42 vs. 27%, p<0.001]); only 28.7% received palliative care.CONCLUSION: HRS was the cause of AKI in 16.5% of patients hospitalised with cirrhosis and conferred significant healthcare burden with 27,180 HRS hospitalisations in 2019 and requiring an estimated 4.2 billion USD for hospital care. While there has been a decrease in in-hospital mortality over time, it remained high at 23.7% in 2019 in those with HRS.

View details for DOI 10.1111/apt.17232

View details for PubMedID 36196562